Quote · The Peter Attia Drive
#403 ‒ Peptides: separating scientific promise from marketing hype
Where this was said
What FDA approval provides when evaluating peptide safety and effectiveness
At 35:00 · chapter starts 34:45
Peter deliberately sidesteps the politically charged love-it-or-hate-it debate about the FDA and asks instead: what information do you gain, and what do you give up, by choosing a drug that has completed formal development versus one that hasn't? The list of what formal development provides is substantial: defined benefit in a defined population, studied dose and formulation, pharmacokinetic profile, characterized safety and contraindications, known drug interactions, monitoring requirements, and manufacturing standards around identity, potency, purity, sterility, and lot-to-lot consistency. FDA approval doesn't mean a drug is perfect or safe forever — drugs get restricted, relabeled, and pulled post-market, which is part of how a properly monitored system is supposed to work. [1] — Peter Attia "Whether you love or hate the FDA is beside the point. Formal drug development gives you defined efficacy in a defined population, a studied…" 34:50 The SS31 example illustrates the context-dependence of approval: a mitochondrial-targeting peptide might reasonably be approved for Barth syndrome, a severe life-limiting disease, on limited evidence, while the same peptide would face an entirely different risk-benefit calculation for a healthy person seeking performance or longevity benefits. What you lose by sticking to approved drugs is early access and cheaper options; what you gain is the evidence and oversight needed to make a defensible decision.
Whether you love or hate the FDA is beside the point. Formal drug development gives you defined efficacy in a defined population, a studied dose, a characterized safety profile, known drug interactions, and manufacturing consistency. Without it, almost all of those questions are unanswered.
